| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ICOS |
| Uniprot No | O75144 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-256aa |
| 氨基酸序列 | DTQEKEVRAMVGSDVELSCACPEGSRFDLNDVYVYWQTSESKTVVTYHIP QNSSLENVDSRYRNRALMSPAGMLRGDFSLRLFNVTPQDEQKFHCLVLSQ SLGFQEVLSVEVTLHVAANFSVPVVSAPHSPSQDELTFTCTSINGYPRPN VYWINKTDNSLLDQALQNDTVFLNMRGLYDVVSVLRIARTPSVNIGCCIE NVLLQQNLTVGSQTGNDIGERDKITENPVSTGEKNAAT |
| 预测分子量 | 52 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ICOS重组蛋白的参考文献示例(注：文献及作者为虚构示例，仅用于演示格式和内容方向)：
---
1. **文献名称**：Structural and Functional Analysis of Recombinant ICOS Protein in T Cell Activation
**作者**：Smith A, et al.
**摘要**：本研究通过哺乳动物表达系统成功制备了重组ICOS蛋白，并解析了其与配体ICOS-L的结合位点。实验表明，重组ICOS能够增强T细胞的增殖和细胞因子分泌，为开发基于ICOS的免疫调节疗法提供了结构基础。
2. **文献名称**：Engineering ICOS-Fc Fusion Protein for Enhanced Anti-Tumor Immunity
**作者**：Chen L, et al.
**摘要**：作者构建了ICOS胞外域与Fc段的融合蛋白(ICOS-Fc)，发现其可通过激活CD4+ T细胞和促进树突状细胞成熟，显著抑制小鼠肿瘤模型中的肿瘤生长，提示重组ICOS-Fc在癌症免疫治疗中的潜在应用。
3. **文献名称**：High-Yield Production of Functional ICOS in E. coli and Its Immunomodulatory Effects
**作者**：Yamamoto K, et al.
**摘要**：该研究优化了ICOS蛋白在大肠杆菌中的可溶性表达和复性工艺，纯化的重组ICOS在体外实验中有效抑制了自身免疫模型中的Th17细胞分化，为低成本生产治疗性ICOS蛋白提供了新策略。
4. **文献名称**：ICOS Recombinant Protein Promotes Follicular Helper T Cell Differentiation In Vitro
**作者**：Garcia R, et al.
**摘要**：通过体外实验验证了重组ICOS蛋白对Tfh细胞分化的促进作用，并发现其与IL-21分泌呈正相关，为疫苗佐剂设计及免疫疾病机制研究提供了实验依据。
---
**说明**：以上文献为示例性内容，实际研究中需检索PubMed、Web of Science等数据库获取真实文献。建议使用关键词“recombinant ICOS protein”、“ICOS signaling”、“ICOS immunotherapy”等进行文献筛选。
ICOS (Inducible T-cell Costimulator), a member of the CD28/CTLA-4 receptor superfamily, is a critical immune checkpoint protein expressed primarily on activated T cells. Discovered in the late 1990s, ICOS interacts with its ligand ICOS-L (B7-H2) on antigen-presenting cells to deliver costimulatory signals for T-cell activation, proliferation, and survival. Structurally, it consists of an extracellular IgV-like domain, transmembrane region, and cytoplasmic tail containing signaling motifs. Unlike CD28. ICOS is not constitutively expressed but induced during T-cell activation, playing a specialized role in regulating effector and follicular helper T-cell responses.
Recombinant ICOS proteins, produced via genetic engineering in systems like mammalian or insect cells, retain the functional extracellular domain for ligand binding. These proteins have become vital tools in immunology research and therapeutic development. They enable mechanistic studies of ICOS-mediated signaling pathways, which influence autoimmune diseases, cancer immunity, and infectious responses. In cancer immunotherapy, ICOS agonists are explored to enhance antitumor T-cell activity, while antagonists may suppress autoimmune conditions. Recombinant ICOS also serves as a critical reagent for antibody screening, structural studies, and biomarker assays. Recent clinical trials targeting the ICOS pathway (e.g., ICOS-agonistic antibodies combined with PD-1 inhibitors) highlight its therapeutic potential. The precise engineering of ICOS recombinant proteins, including Fc-fusion variants and species-specific isoforms, continues to advance both basic research and translational applications in immune modulation.
×
